{
  "meta": {
    "publisher": "Mass Tort Marketing Agency",
    "dataset": "Cost Per Signed Retainer (CPR) Benchmark",
    "release": "2026-q1",
    "quarter": "Q1 2026",
    "temporalCoverage": "2026-01-01/2026-03-31",
    "dataAsOf": "2026-03-31",
    "published": "2026-04-24",
    "lastReviewed": "2026-06-10",
    "methodologyVersion": "1.0",
    "methodologyUrl": "https://www.masstortmarketingagency.com/benchmarks/methodology",
    "canonicalUrl": "https://www.masstortmarketingagency.com/benchmarks/olympus-scope",
    "verification": {
      "status": "unverified",
      "reviewer": null,
      "statement": "No third party has reviewed this methodology or the underlying data. Mass Tort Marketing Agency sells the leads these figures price."
    },
    "vendorDisclosure": "Mass Tort Marketing Agency sells the mass tort leads these figures price. The panel is the agency's own client base and the underlying performance data is self-reported by those firms.",
    "sourcesDisclosure": "Benchmark ranges are drawn from the panel performance data cross-referenced against published industry surveys and practitioner-disclosed benchmarks. Those sources are not named in the published methodology, and how they enter the calculation is not specified.",
    "license": {
      "name": "CC BY 4.0",
      "url": "https://creativecommons.org/licenses/by/4.0/",
      "attribution": "Mass Tort Marketing Agency CPR Benchmark, https://www.masstortmarketingagency.com/benchmarks/"
    },
    "nullConvention": "A null value is never a zero and never an estimate. Every null is paired with an adjacent *Reason field stating why the value is unavailable.",
    "snapshotUrl": "https://www.masstortmarketingagency.com/benchmarks/data/2026-q1.json"
  },
  "tort": {
    "slug": "olympus-scope",
    "name": "Olympus Scope (CRE infection, MAJ-891 recall)",
    "status": "Active",
    "cpr": {
      "low": 5200,
      "median": null,
      "medianUnavailableReason": "Per-tort medians are not published. The dataset carries the interquartile low and high bounds for each tort; only the national median is published as a point value.",
      "high": 7600,
      "currency": "USD"
    },
    "signedRatePct": {
      "low": 6,
      "high": 10
    },
    "qualificationTier": "Very High",
    "sampleSize": null,
    "sampleSizeUnavailableReason": "Per-tort sample sizes are not broken out in the published dataset. The panel total (140 firms, $180M of annual mass tort lead spend across 16 active tort categories) is published at the panel level only, so the number of firms and the spend basis behind any single row cannot be stated.",
    "confidenceInterval": null,
    "confidenceIntervalUnavailableReason": "Not computable from the published dataset. Benchmarks are published as trimmed interquartile ranges, and the per-observation values a confidence interval requires are not retained in the published figures.",
    "falloffPct": null,
    "falloffUnavailableReason": "Not published for this tort. The source dataset does not state a numeric falloff range for Olympus Scope.",
    "falloffNote": null,
    "rowUpdated": "2026-04-24",
    "rowUpdatedNote": "Rows are refreshed as a complete set each release, so every row carries the release publication date rather than an independent per-row date.",
    "qualificationCriteria": "A documented Olympus scope procedure (typically ERCP, cystoscopy, ureteroscopy, or a procedure using the recalled MAJ-891 tubing set), plus a documented CRE or other qualifying bacterial infection within approximately 30 days, plus hospitalization records.",
    "statusAndAcquisition": "Active, with the most demanding qualification criteria in the benchmark. The CPR is worth the investment because case values are unusually high — the Bigler bellwether verdict delivered $6.6 million plus $250,000 in concealment sanctions, and bellwether planning suggests average settlement values in the high six figures for serious CRE cases. Firms with medically-trained intake capable of navigating ERCP procedure records plus infection-diagnosis records outperform general-intake firms by 25-35% on signed rate.",
    "relatedTorts": [
      "oxbryta",
      "pfas-personal-injury",
      "bard-powerport"
    ],
    "canonicalUrl": "https://www.masstortmarketingagency.com/benchmarks/olympus-scope",
    "quarter": "Q1 2026"
  },
  "series": {
    "low": [
      {
        "release": "2024-q4",
        "label": "Q4 2024",
        "dataAsOf": "2024-12-31",
        "value": null,
        "valueReason": "No per-tort breakdown for Q4 2024 is held in the dataset. Only the national median is held for that quarter, which is why the per-tort trend series begins at Q1 2026."
      },
      {
        "release": "2026-q1",
        "label": "Q1 2026",
        "dataAsOf": "2026-03-31",
        "value": 5200,
        "valueReason": null
      }
    ],
    "high": [
      {
        "release": "2024-q4",
        "label": "Q4 2024",
        "dataAsOf": "2024-12-31",
        "value": null,
        "valueReason": "No per-tort breakdown for Q4 2024 is held in the dataset. Only the national median is held for that quarter, which is why the per-tort trend series begins at Q1 2026."
      },
      {
        "release": "2026-q1",
        "label": "Q1 2026",
        "dataAsOf": "2026-03-31",
        "value": 7600,
        "valueReason": null
      }
    ]
  },
  "annotations": []
}